ClinicalTrials.gg
CompletedNCT04386187GSHUpdated Jan 21, 2022

Glutathione-rich Foods for Type 2 Diabetes

An interventional study of GSH Foods and Nutrition education about glutathione sources in the diet in Type 2 Diabetes, sponsored by University of California, San Diego. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research study is to find out whether certain plant-based foods may be beneficial for individuals with type 2 diabetes. To meet the goal, study participants will be fed known amounts of foods and nutrients. Before and after participants have eaten the food, they will self-measure height, weight, and waist circumference and study staff will administer questionnaires. Blood samples will be taken at a local lab to measure blood sugar and blood lipids.All study appointments will be conducted online.

Read the detailed description

This research study is a randomized, controlled trial that will evaluate whether diet and nutrition education on, and short-term partial feeding of, specific plant foods high in the antioxidant glutathione will impact total glutathione status, gamma-glutamyltransferase (GGT) activity, glucose control or insulin sensitivity in people with type 2 diabetes. Dietary education will include information on plant sources of glutathione, as well as, cooking methods to reduce glycation and lipid peroxidation during cooking, which may indirectly alter glutathione status by reduce demand for elimination of these compounds. Participants will be randomized to one of two groups: the educational intervention plus partial feeding of two small meals per day vs. a wait list control group that will receive standard advice on nutrition for diabetes. After 12 weeks, the intervention group will no longer receive foods, but will be followed for 12 additional weeks to determine if lasting effects are achieved. After 12 weeks, the control group will receive access to the educational materials, but will not receive study foods, to see if the educational intervention alone impacts food/nutrition choices. Both groups will have lab measures (as described above) again after this additional 12 weeks, for a total duration of 24 weeks in the trial.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • Glutathione
  • Nutrition
03

In context

Diabetes Mellitus, Type 2

9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.

This study's enrollment of 12 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

University of California, San Diego is the lead sponsor of 975 studies on the registry; 196 are open to participants now.

Of its 111 completed or terminated interventional studies of FDA-regulated products, 71 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • Ages 18 to 65
  • Type 2 diabetes
  • Free of self-reported acute and confounding chronic diseases (e.g., heart failure, kidney disease, liver disease, gastrointestinal disorder) based on a standardized medical history questionnaire
  • Free of alcoholism, smoking and major cardiovascular event with the past 6 months
  • Not on insulin to help manage diabetes
  • Planning on staying in the San Diego area for the next 6 months
  • Willing to select plant-based foods from a "menu" and eat the selected foods provided by the study team
  • Have access to the internet and a computer
  • Willing to view 4 weekly educational classes online, followed by periodic telephone and email contacts
  • Agree to schedule and complete periodic questionnaires and measurements during up to four total online appointments

Exclusion criteria

Exclusion Criteria:

  • Alcoholism, smoking and recent cardiovascular events
  • Individuals will be excluded if they report any dietary restrictions, allergies or preferences
  • Unsuitability based on screening visit
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Arm 1: Experimental Feeding

    Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.

    Other: GSH Foods · Other: Nutrition education about glutathione sources in the diet

  • Active comparator
    Arm 2: Education Control

    Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.

    Other: Standard of care nutrition education for type 2 diabetes

Interventions

  • OtherGSH Foods

    The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).

  • OtherNutrition education about glutathione sources in the diet

    Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.

  • OtherStandard of care nutrition education for type 2 diabetes

    The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.

06

What researchers measure

Primary outcomes

  1. Total glutathione

    Total glutathione concentration in the blood

    Time frame: 12 weeks

  2. gamma-glutamyltransferase (GGT)

    Measure of glutathione demand in the blood

    Time frame: 12 weeks

Secondary outcomes

  1. Fasting glucose

    Serum glucose concentration while fasting

    Time frame: 12 weeks

  2. Fasting insulin

    Plasma insulin concentration while fasting

    Time frame: 12 weeks

  3. Hemoglobin A1c

    Measure of glycemic control

    Time frame: 12 weeks

  4. Homeostasis Assessment Index of Insulin Resistance (HOMA-IR)

    Estimate of insulin resistance

    Time frame: 12 weeks

  5. Low density lipoprotein concentration (LDL-c)

    concentration of LDL lipoproteins in serum

    Time frame: 12 weeks

  6. High density lipoprotein concentration (HDL)

    concentration of HDL lipoproteins in serum

    Time frame: 12 weeks

  7. Triglycerides

    concentration of triglycerides in serum

    Time frame: 12 weeks

Other outcomes

  1. Total glutathione

    Total glutathione concentration in the blood

    Time frame: 24 weeks

  2. gamma-glutamyltransferase (GGT)

    Measure of glutathione demand in the blood

    Time frame: 24 weeks

  3. Fasting insulin

    Plasma insulin concentration while fasting

    Time frame: 24 weeks

  4. Fasting glucose

    Serum glucose concentration while fasting

    Time frame: 24 weeks

  5. Hemoglobin A1c

    Measure of glycemic control

    Time frame: 24 weeks

  6. Homeostasis Assessment Index of Insulin Resistance (HOMA-IR)

    Estimate of insulin resistance

    Time frame: 24 weeks

  7. Low density lipoprotein concentration (LDL-c)

    concentration of LDL lipoproteins in serum

    Time frame: 24 weeks

  8. High density lipoprotein concentration (HDL)

    concentration of HDL lipoproteins in serum

    Time frame: 24 weeks

  9. Triglycerides

    concentration of triglycerides in serum

    Time frame: 24 weeks

07

Study locations

1 site
  • University of California, San Diego
    San Diego, California 92093, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04386187
Responsible party
Ryan Bradley (Assistant Professor, University of California, San Diego) — Principal investigator
First posted
May 13, 2020
Start date
Jul 28, 2020
Primary completion
Apr 2, 2021
Completion
Apr 2, 2021
Last update
Jan 21, 2022

Study contacts

Ryan Bradley, ND, MPH
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion